Immunic (IMUX) Cash from Financing Activities (2013 - 2026)

Immunic has disclosed Cash from Financing Activities across 14 years of filings, most recently posting $188.6 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $188.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $254.2 million (up 330054.55% YoY), and the FY2025 annual result was $65.6 million, down 12.03% from the prior year.
• Cash from Financing Activities came in at $188.6 million for Q1 2026 at Immunic, up from $59000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $188.6 million in Q1 2026 to a low of $51000.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $5.3 million (2022), against an average of $35.5 million.
• Across the five-year window, Cash from Financing Activities plunged 99.83% in 2023 and surged 145907.84% in 2024, its largest moves.
• Immunic's Cash from Financing Activities stood at $56.0 million in 2022, then slumped by 98.92% to $604000.0 in 2023, then plunged by 87.25% to $77000.0 in 2024, then declined by 23.38% to $59000.0 in 2025, then soared by 319632.2% to $188.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $188.6 million (Q1 2026), $59000.0 (Q4 2025), and $65.5 million (Q2 2025), per Business Quant data.